Almirall launches MC2 Therapeutics-developed psoriasis cream in Europe

Skin health firm Almirall is initiating the European launch of plaque psoriasis cream Wynzora, which the Spanish company acquired the rights for through a licensing agreement with Danish firm MC2 Therapeutics last year.
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

Last year, Spanish dermatology firm Almirall entered a license and commercialization agreement with Danish MC2 Therapeutics, gaining the European rights for the latter company’s plaque psoriasis cream, Wynzora.

Almirall has now initiated the launch of the cream in Europe, the company announces in a press release.

The rollout will begin on the Spanish, German and UK markets, with more European markets expected to follow in coming months.

”The launch of Wynzora cream in Europe represents a step forward in our commitment to offering innovative therapies that improve the quality of life of patients with psoriasis,” says CEO at Almirall Gianfranco Nazzi in the statement, adding:

”Currently, 73 percent of patients are not adhering to topical treatments. In view of this worrying lack of adherence to such treatments, Almirall is convinced that this new product, with proven efficacy and a patient-friendly formulation, will mark a turning point by improving psoriasis patients’ satisfaction thanks to its less greasy formulation.”

MC2 Therapeutics launched Wynzora on the US market last year, in a collaboration with Epi Health.

Express Scripts to cover psoriasis cream from MC2 Therapeutics

MC2 Therapeutics launches psoriasis cream in US

Almirall partner MC2 on the verge of EU victory after ten years of hard work

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading